Brought to you by 
Second Genome completes $5mm Series A financing; adds $6.5mm
06 Jun 2013
Executive Summary
First-time backers Advanced Technology Ventures and Morgenthaler Ventures have led a $5mm Series A financing for personalized GI medicines start-up Second Genome Inc. (formerly PhyloTech). An executive from each VC contributes a board member. Ten other investors participated, including existing shareholders Wavepoint Ventures, Seraph Group, and individual seed backers.
Deal Industry
- Pharmaceuticals
- Services
-
Pharmaceuticals
- Nutraceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Bioinformatics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Second Genome completes $5mm Series A financing; adds $6.5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice